Anticoagulants
Moderate
Database
Theoretical antagonism of anticoagulant effect; may increase thrombosis risk
Monitor coagulation parameters; use with caution
Source: Kimi deep-research + Cla
Drug reference
Ethamsylate
Hemostatic agent / capillary stabilizer · Antihemorrhagic
Also known as Dicynene, Emsylate, Styptocid
START
250-500 mg TDS-QDS for active bleeding; 250-500 mg 1h pre-op for surgical prophylaxis
TYPICAL MAX
2000 mg/day
STOP IF
Signs of thrombosis, severe allergic reaction
WATCH
Bleeding time, signs of thrombosis
CDSCO approvedSchedule HJan AushadhiNPPA price-controlledATC B02BX01
KDIGO 2024 + manufacturer label
- ONSET
- 23min · absorption onset
- PEAK
- 1.5h · Peak plasma concentration
- t½
- 4h · Elimination half-life
- DURATION
- 8h · Duration of effect
EXCRETION
Renal (metabolites)
route + CYP
INTERACTIONS
—
none in our sources
PREGNANCY
Avoid in first trimester; use with caution in second and third trimesters
FDA category + note
Available in India
258 branded formulations and 149 fixed-dose combinations. Look up specific brands in the Drugs workspace.
Jan Aushadhi — generic available at GoI pharmacies
Mechanism
Reduces capillary permeability and stabilizes vascular endothelium; promotes platelet aggregation and adhesion by increasing cyclic-AMP in platelets; may also enhance prostacyclin synthesis
Indications
Prevention and treatment of capillary bleedingMenorrhagiaPerioperative bleeding prophylaxisEpistaxisBleeding after dental extraction
Dosing
- Adult
- 250-500 mg 2-4 times daily; perioperative: 250-500 mg 1 hour before surgery then every 6 hours for 24-48 hours
- Pediatric
- Not recommended in children
- Renal adjustment
- No specific adjustment needed; limited data
- Hepatic adjustment
- No specific adjustment needed; limited data
- Geriatric
- Standard dosing; monitor for thrombotic events
- Max dose
- 2000 mg/day
Pharmacokinetics
Onset
4-6 hours (hemostatic effect)
Peak effect
1-2 hours (Tmax)
Duration
8 hours
Half-life
3-5 hours
Bioavailability
~90%
Protein binding
~80%
Metabolism
Hepatic glucuronidation and sulfation
Excretion
Renal (primarily as metabolites)
Contraindications
- Hypersensitivity to ethamsylate
- Acute porphyria
Side effects
Common
NauseaHeadacheRashPyrexia
Serious
- Thromboembolic events (theoretical)
- Severe allergic reactions
- Acute porphyria exacerbation
Pregnancy & lactation
Pregnancy
Avoid in first trimester; use with caution in second and third trimesters
Lactation
Excretion in breast milk unknown; use with caution during breastfeeding
Drug interactions
Thrombolytics
Moderate
Database
Potential reduction of thrombolytic efficacy
Avoid concurrent use if possible
Source: Kimi deep-research + Cla
Nsaids
Mild
Database
May have additive effects on platelet function
Monitor for bleeding or clotting abnormalities
Source: Kimi deep-research + Cla
Oxytocin
Mild
Database
Both used in obstetric bleeding; no direct interaction
Can be used together in postpartum hemorrhage
Source: Kimi deep-research + Cla
Tranexamic Acid
Mild
Database
Complementary hemostatic mechanisms; no adverse interaction
Can be combined in severe bleeding protocols
Source: Kimi deep-research + Cla
4 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.
Related guidelines
Infective endocarditis prevention
NICE · Cardiology / Dentistry · 2008
Infective endocarditis prevention
AHA · Cardiology / Dentistry · 2007
Infective endocarditis prevention
ADA_DENTAL · Dentistry · 2015
GI bleeding on antiplatelet or anticoagulant therapy
CSI · Cardiology · 2020
Acute dental pain and intraoral swelling
ADA_DENTAL · Dentistry · 2019
Ask House about Ethamsylate
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e·Updated: 2026-05-19·Cockpit curated: 2026-05-19